All News

Article

RA Patients on Biologics and tsDMARDs are still High Risk

Jack Cush, MD Apr 12, 2023

A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.

Article

Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis

Jack Cush, MD Apr 12, 2023

A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.

Methotrexate-induced pneumonitis (0.3% risk) is different than RA-ILD. MTX does not increase odds of RA-ILD. @jeffsparks @UTSW_Rheum https://t.co/JV1CcB0sLP

Japanese cohort study shows Lung cancer is more common in males w/ elder-onset dermatomyositis - risk increased by Smoking, anti-TIF1-γ-Abs and elevated MLR (monocyte to lymphocyte ratio) https://t.co/LlTkiWp7pb https://t.co/Bu9atnI8je

https://bit.ly/3mC08Kl

Disease activity increases the risk of future RA-ILD. For every one point increase in DAS28, theres a 35% increase risk of RA-ILD @jeffsparks @UTSW_Rheum https://t.co/P3dNDVanuL

MUC5B is a common genetic variant (~12%) that is strongly assoc w/ IPF, but also RA-ILD (3.1-4.7 fold risk) @jeffsparks @UTSW_Rheum https://t.co/t1Kgmj8a3x

Survival in RA-ILD is reduced (data from two different eras) @jeffsparks @UTSW_Rheum https://t.co/7eGgGnEgwW

Risk of RA-ILD is 15% (or 1 in 6) according to Mayo clinic (Olmstead county) data. @jeffsparks https://t.co/KynitLCsK7

#RA with ILD portends poor outcomes, especially if seropositive. Visiting professor Dr. Jeff sparks @jeffsparks @UTSW_Rheum https://t.co/fbVyDMUm6L

Rheumatologist - Work-Life Survey Results Last week, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA. https://t.co/2g7oL6ltAo https://t.co/uYv7sDyO9o

https://bit.ly/3mtFhZA

Dr. Megan Clowse discusses the differences in pregnancy planning for men and women with rheumatic disease, with particular focus on medication use. Watch now. https://t.co/Ine8CdbZR4 https://t.co/7UnanlnQcC

https://bit.ly/3Kod7r1

FDA FAERS study of IL-17 inhib & colitis: 388 pts w/ suspected IL-17i assoc. IBD. Median age - 42 yrs; Initial Sxs= diarrhea 91%, Abd pain 58%, bloody diarrhea 51%), & fever 36%, ^WBC 87%; Time to onset=2.9 mos. Time to remission after IL-17i D/C =4 wks https://t.co/adrtUhFj9C https://t.co/61GC5hvzYV

https://bit.ly/40Vfokr

Retrospective study of 42 pts w/ cocaine-induced midline or systemic vasculitis; Current cocaine use common (20/23 + urine tox, including pts who prev. deniedcocaine). Found: septal perfs (75%), oronasal fistula(15%), less(27%) systemic Sxs, 56% PR3-ANCA+https://t.co/z1Z4INRSj5 https://t.co/v9ZyZD1Lrb

https://bit.ly/40VEH67

With AI and GPT-4... "The cognitive speed limit has just been lifted." - John Nosta https://t.co/mMXos8LLt6 https://t.co/imBfp37J1l

https://bit.ly/3UtS4Ii

Spanish Society of Rheumatology (SER) study finds w/ retirement of many older (male) Rheums; there are workforce shortages. Most (59.7%) of rheums in Spain are women, the majority below age 54 yrs. https://t.co/DPs0S63Aqc https://t.co/ig4kOQWmkn

https://bit.ly/415gqds

vit D shows no change in Fx Risk. Study of 20,326 Australians given placebo or vit D3 60K IU/mo. 46% women, age 69 yrs. W/ 5.1 yrs F/U - no effect on Fx risk (HR 0·94; 0·84–1·06). Fx in 5.6% of Vit D vs 5.9% in PBO (non-vertebral, major OP & hip Fxs https://t.co/cSbTS3xWrX https://t.co/Jipzw28Wn8

https://bit.ly/3mcMygA

Antiphospholipid Antibodies With Incident Cardiovascular Events Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk? https://t.co/XQk17P6D2f https://t.co/y5exrsicW8

https://bit.ly/3nOx6r9

RheumThoughts: Changing the Conversation with Patients: Lupus Join the discussion! RheumThoughts are opinion pieces from healthcare professionals. https://t.co/NcJcCZVlbE @drbags71 https://t.co/VfAqUkqLak

https://bit.ly/41n0OlK

RheumNow Presents Women In Rheumatology: Contract Negotiations https://t.co/nkAu5kQj2w

https://twitter.com/i/broadcasts/1gqGvyplPvWKB

TONIGHT! Tuesday Night Rheumatology addresses Contract Negotiations, featuring Andrea Liberatore, JD, Gwenesta Melton, MD, and Kathryn Dao, MD. Sign up to attend this and all of our Tuesday Night Rheumatology series. @uptoTate @KDAO2011 https://t.co/L2WMLnnJhV https://t.co/Z4kEBJHBjz

https://bit.ly/3zKvlxZ

Topics

All News

RA Patients on Biologics and tsDMARDs are still High Risk

Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis

Do you get our email newsletter?